Pognostic estimation of arterial stiffness, pulmonary hypertension and epicardial fat thickness in comorbid patients

The article presents the results of a study aimed at examining the relationship between arterial stiffness (AS), pulmonary hypertension (PH), and epicardial fat thickness (EFT) in patients with ischemic heart disease (IHD) and arterial hypertension (AH) combined with emphysematous and bronchitic phenotypes of chronic obstructive pulmonary disease (COPD).

Material and methods. The study included 68 patients with IHD, AH, and bronchitic phenotype of COPD (Group 1) and 55 patients with emphysematous phenotype of COPD (Group 2); 22 patients with IHD and AH without COPD (Group 3).

Results. The study revealed higher AS indicators (pulse wave velocity, augmentation index, central systolic and central pulse arterial pressure) associated with increased PH and EFT, as well as diastolic heart dysfunction in patients with IHD, AH, and bronchitic variant of COPD. It also identified key directions for etiopathogenetic therapy for these patients with frequent comorbid conditions.

Conclusion. In complex cases of comorbid pathology involving IHD and AH, it is important to clarify the COPD phenotype to prescribe appropriate etiopathogenetic therapy.

1. Agababyan I.R., Ismailov J.A., Turdibekov H.I., Shodieva G.R., Ruzieva A.A. Study of the state of the cardiovascular system in COPD. Science and Education Achievements. 2019:10(51). (In Russian).

2. Abdurakhmanov Z.M., Umarov B.Y., Abdurakhmanov M.M. Modern biomarkers of endothelial dysfunction in cardiovascular diseases. Rational pharmacotherapy in cardiology. 2021;17(4):612-618. (In Russian). DOI:10.20996/1819-6446-2021-08-08

3. Gataova Z.M., Merzhoeva M.V., Merzhoeva M.V. Vascular aging in patients with arterial hypertension and coronary heart disease: correction of endothelial dysfunction and arterial stiffness. Actual issues of medicine. 2022:129–132. (In Russian).

4. Bezverkhov A.A., Ischenko O.Yu. Dynamics of mortality from cardiovascular diseases for the period 2015–2019. Norwegian Journal of International Science Development. 2021;54(2):35–38. (In Russian). DOI: 10.24412/3453-9875-2021-54-2-35-38

5. Kalashnik D.N., Korolchuk I.S. Comorbid patient with chronic obstructive pulmonary disease and ischaemic heart disease: possibilities of early diagnosis of pulmonary hypertension in outpatient settings. Medical Council. 2021;12:146–153. (In Russian). DOI: 10.21518/2079-701X-2021-12-146-153

6. Maychuk E. Yu, Voevodina I. V., Vyzhigin D. A. Arterial stiffness and comorbid pathology. Terapiya. 2020;6(2):123–130. (In Russian). DOI: 10.18565/therapy.2020.2.123-130

7. Prozorovskaya Yu.I., Kostyushok N.Y., Golubtsova G.A, Pavlyuchenko I.I., Gusaruk L.R. Features of metabolic shifts in patients with chronic obstructive pulmonary disease of different phenotype. International Research Journal. 2021;8(110). Part 2. (In Russian). DOI: 10.23670/IRJ.2021.110.8.060

8. Sobko E.A., Chubarova S.V., Demko I.V., Loktionova M.M., Ischenko O.P., Solovieva I.A., Kraposhina A.Yu., Gordeeva N.V. ACOS-syndrome: clinical and functional features. Therapeutic Archive. 2017;89(12):68–75. (In Russian)]. DOI: 10.17116/terarkh2017891268-75

9. Nakayama S., Chubachi S., Sakurai K. et al. Characteristics of chronic obstructive pulmonary disease patients with pulmonary hypertension assessed by echocardiography in a three-year observational cohort study. Int. J. Chron. Obstruct. Pulmon. Dis. 2020;15:487–499. DOI:10.2147/COPD.S230952

10. Chaulin A.M., Grigorieva Y.V., Dupliakov D.V. Comorbidity of chronic obstructive pulmonary disease and cardiovascular disease: common factors, pathophysiological mechanisms and clinical significance. Clinical Practice. 2020;11(1):112–121. DOI: 10.17816/clinpract21218

11. Chuchalin A.G. et al. Chronic obstructive pulmonary disease: federal clinical recommendations for diagnosis and treatment. Pulmonology. 2022;32(3):356–392. (In Russian). DOI: 10.18093/0869-0189-2022-32-3-356-392

12. Blanco I, Tura-Ceide O, Peinado VI, Barberà JA. Updated Perspec tives on Pulmonary Hypertension in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2020;15:1315–1324. DOI: 10.2147/COPD.S211841.

13. Boutouyrie P. et al. Arterial stiffness and cardiovascular risk in hypertension. Circulation research. 2021;128(7):864–886. DOI: 10.1161/CIRCRESAHA.121.318061

14. Duan R.R., Hao K., Yang T. Air pollution and chronic obstructive pulmonary disease. Chronic diseases and translational medicine. 2020;6(4):260–269. DOI: 10.1016/j.cdtm.2020.05.004

15. Elia D, Caminati A., Zompatori M., Cassandro R., Lonati C., Luisi F., Pelosi G., Provencher S., Harari S. Pulmonary hypertension and chronic lung disease: where are we headed? Eur. Respir. Rev. 2019;28(153):190065. DOI: 10.1183/16000617.0065-2019

16. MacLeod M. et al. Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact. Respirology. 2021;26(6):532–551. DOI: 10.1111/resp.14041

17. Drapkina O.M., Shepel R.N., Deeva T.A. Epicardial fat thickness — a ‘visiting card’ of the metabolic syndrome. Obesity and Metabolism. 2018;15(2):29–34. (In Russian). DOI: 10.14341/omet9295

18. Miravitlles M., Soler-Cataluña J.J., Calle M., Molina J., Almagro P., Quintano J.A., Trigueros J.A., Cosío B.G., Casanova C., Antonio Riesco J., Simonet P., Rigau D., Soriano J.B., Ancochea J. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. Arch. Bronconeumol. 2017;53(6):324–335. DOI: 10.1016/j.arbres.2017.03.018

19. Tsai J P., Hsu B.G. Arterial stiffness: A brief review. Tzu-Chi Medical Journal. 2021;33(2):115. DOI: 10.4103/tcmj.tcmj_44_20

20. Stolz D. et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. The Lancet. 2022;400(10356):921–972. DOI: 10.1016/S0140-6736(22)01273-9

21. Ritchie A.I., Wedzicha J.A. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clinics in chest medicine. 2020;41(3):421–438. DOI: 10.1016/j.ccm.2020.06.007